Arrhythmia following allogeneic hematopoietic stem-cell transplantation (allo-HSCT) can be seen in association with fluid overload, dimethyl sulfoxide (DMSO), and cyclophosphamide. Its cause remains unclear in most cases.
A 43-year-old man with myelodysplastic syndrome underwent allo-HSCT from a matched unrelated donor after conditioning with cyclophosphamide 60 mg/kg for 2 days and busulfan 4 mg/kg for 4 days. Graft-versus-host disease (GVHD) prophylaxis was a continuous infusion of cyclosporine 3 mg/kg and short-course methotrexate. Serum concentration of cyclosporine was maintained between 250 and 400 ng/dl. On day 19, he developed acute GVHD, which was successfully treated with methylprednisolone. On day 23, serum cyclosporine level was elevated to 450 ng/dl. His heart rate was 30-40/min. Electrocardiogram revealed sinus bradycardia. Echocardiography showed no abnormalities. He had presyncope with severe diaphoresis on day 24, which responded to isoproterenol. All medications other than methylprednisolone were discontinued: cyclosporine, fluconazole, acyclovir, vancomycin, and panipenem. His condition gradually improved and his heart rate increased to 80-100/min. When we discontinued isoproterenol on day 26, no bradycardia recurred. Since cyclosporine is essential for GVHD prophylaxis, we needed to investigate the association between cyclosporine and bradycardia. After obtaining his informed consent, we resumed cyclosporine on day 35. On day 37, bradycardia and presyncope recurred (Figure 1 ). After discontinuation of cyclosporine, his heart rate normalized. GVHD prophylaxis was switched to tacrolimus, and its serum concentration was maintained between 5 and 10 ng/dl. Thereafter, bradycardia did not recur. Electrophysiological study on day 86 revealed neither sinus node dysfunction nor atrioventricular conduction abnormality.
The clinical course of this patient demonstrates a dosedependent association between sinus bradycardia and cyclosporine (Figure 1 ). These findings are consistent with the previous reports on solid organ transplantation, which documented cyclosporine-associated sinus bradycardia in 37 of 50 cases.
1 Sinus bradycardia has not been documented in large phase III studies comparing cyclosporine with tacrolimus in allo-HSCT. 2 The difference between solid organ transplantation and allo-HSCT might be attributable to the lower dosage of cyclosporine in allo-HSCT than that in organ transplant recipients. 3 Two mechanisms may underlie cyclosporine-associated bradycardia. Cyclosporine may suppress automaticity of the sinus node. Sinus arrest has been reported in patients given cyclosporine. 4 An electrophysiological study performed after cyclosporine had been discontinued failed to show any abnormality in the sinus node in this patient. As an alternative possibility, cyclosporine might have stimulated the parasympathetic nervous system and led to bradycardia; with diaphoresis being the result of compensatory increase in the sympathetic nervous system activity. However, cyclosporine has been reported to suppress the parasympathetic nervous function such as baroreflex, 5 suggesting that the second possibility is less likely.
Our observation suggests that cyclosporine could be a rare cause of sinus bradycardia in allo-HSCT recipients. Serum concentration of cyclosporine should be carefully monitored in patients with sinus bradycardia. The dose-dependent association of serum cyclosporine levels and heart rate. When the cyclosporine level was as high as 400 ng/dl, the heart rate decreased to 30s. The decrease in the heart rate was repeatedly demonstrated with cyclosporine challenge on day 37.
